Can a spray alter skin bacteria to help lymphoma lesions?
NCT ID NCT05728879
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a wound spray (APR-TD011) on skin lesions caused by cutaneous T cell lymphoma. Researchers want to see if the spray can reduce harmful bacteria (Staphylococcus aureus) on the skin and if it is well tolerated. The study will include 30 adults with early-stage mycosis fungoides. It is a pilot study, meaning it is a small first step to gather information, not a treatment for the lymphoma itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology CTU
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A microchip implanted in tumors could reveal which drugs work best
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?
- Combination therapy aims to boost response in rare skin cancers
- Can a tailored exercise and diet plan beat cancer fatigue?
- New cream targets skin lymphoma without steroids